1. Home
  2. MDXH vs MIST Comparison

MDXH vs MIST Comparison

Compare MDXH & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.82

Market Cap

183.4M

Sector

N/A

ML Signal

HOLD

Logo Milestone Pharmaceuticals Inc.

MIST

Milestone Pharmaceuticals Inc.

HOLD

Current Price

$1.95

Market Cap

176.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDXH
MIST
Founded
2003
2003
Country
Belgium
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
183.4M
176.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
MDXH
MIST
Price
$3.82
$1.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$7.67
$8.50
AVG Volume (30 Days)
151.4K
3.4M
Earning Date
02-26-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$103,069,000.00
N/A
Revenue This Year
$23.34
N/A
Revenue Next Year
$22.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.68
N/A
52 Week Low
$1.35
$0.63
52 Week High
$5.33
$3.06

Technical Indicators

Market Signals
Indicator
MDXH
MIST
Relative Strength Index (RSI) 55.75 41.12
Support Level $3.56 $1.97
Resistance Level $4.34 $2.06
Average True Range (ATR) 0.27 0.12
MACD 0.07 0.00
Stochastic Oscillator 61.19 18.75

Price Performance

Historical Comparison
MDXH
MIST

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Share on Social Networks: